The estimated Net Worth of Misha Petkevich is at least $394 Tisíc dollars as of 28 October 2021. Mr. Petkevich owns over 167,000 units of CohBar Inc stock worth over $175,272 and over the last 5 years he sold CWBR stock worth over $0. In addition, he makes $218,282 as Independent Director at CohBar Inc.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Mr. Petkevich CWBR stock SEC Form 4 insiders trading
Misha has made over 4 trades of the CohBar Inc stock since 2020, according to the Form 4 filled with the SEC. Most recently he bought 167,000 units of CWBR stock worth $96,860 on 28 October 2021.
The largest trade he's ever made was buying 204,918 units of CohBar Inc stock on 28 August 2020 worth over $88,115. On average, Misha trades about 64,820 units every 71 days since 2019. As of 28 October 2021 he still owns at least 407,609 units of CohBar Inc stock.
You can see the complete history of Mr. Petkevich stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Misha Petkevich biography
Misha Petkevich Ph.D. serves as Independent Director of the Company. He joined our Board in October 2019. Mr. Petkevich has more than 30 years of financial and investment experience in biotechnology and investment banking. Since 2015, Mr. Petkevich has been the Chief Investment Officer of V2M Capital, an investment firm funding life science companies. He currently serves on the board of directors of HingeBio, Inc., a biotechnology company developing bispecific and multispecific antibodies. In 2005, he co-founded BladeRock Capital, LLC, an investment firm specializing in life science companies. Prior to founding BladeRock Capital, Mr. Petkevich founded The Petkevich Group, a biotechnology advisory firm, where he was Chairman and Chief Executive Officer from 1998 to 2005. Between 1989 and 1998, Mr. Petkevich served as Managing Director, as well as Head of Healthcare and Investment Banking at Robertson Stephens & Co. Mr. Petkevich began his career at Hambrecht & Quist, an investment bank, where he served as a Principal, Head of Healthcare Banking and as a biotechnology analyst covering Genentech, Chiron and others. Mr. Petkevich received his bachelor’s degree from Harvard University and his DPhil from the University of Oxford. Mr. Petkevich’s industry, investment and financial advisory experience make him an important contributor to our Board.
What is the salary of Misha Petkevich?
As the Independent Director of CohBar Inc, the total compensation of Misha Petkevich at CohBar Inc is $218,282. There are 8 executives at CohBar Inc getting paid more, with Steven Engle having the highest compensation of $2,410,850.
How old is Misha Petkevich?
Misha Petkevich is 70, he's been the Independent Director of CohBar Inc since 2019. There are 1 older and 12 younger executives at CohBar Inc. The oldest executive at CohBar Inc is Albion Fitzgerald, 71, who is the Independent Chairman of the Board.
What's Misha Petkevich's mailing address?
Misha's mailing address filed with the SEC is C/O COHBAR, INC., 1455 ADAMS DRIVE, SUITE 2050, MENLO PARK, CA, 94025.
Insiders trading at CohBar Inc
Over the last 7 years, insiders at CohBar Inc have traded over $0 worth of CohBar Inc stock and bought 586,523 units worth $136,480 . The most active insiders traders include Misha Petkevich, Kenneth C Cundy a Jon Leland Stern. On average, CohBar Inc executives and independent directors trade stock every 22 days with the average trade being worth of $9,727. The most recent stock trade was executed by David Greenwood on 1 November 2021, trading 20,000 units of CWBR stock currently worth $8,600.
What does CohBar Inc do?
cohbar (otcqx: cwbr and tsxv: cob.u) is the leader in the research and development of mitochondria-based therapeutics (mbts), an emerging class of drugs for the treatment of diseases associated with aging. mbts originate from the discovery of a novel group of peptides within the genome of mitochondria, the powerhouses of the cell. this groundbreaking discovery was made by our founders, world leaders in the biology of aging, metabolism and mitochondrial genomics. mbts offer the potential to address a broad range of diseases such as type 2 diabetes, cancer, atherosclerosis and neurodegenerative disorders.
What does CohBar Inc's logo look like?
Complete history of Mr. Petkevich stock trades at CohBar Inc
CohBar Inc executives and stock owners
CohBar Inc executives and other stock owners filed with the SEC include:
-
Steven Engle,
Chief Executive Officer, Director -
Phyllis Gardner,
Independent Director -
Dr. Kenneth C. Cundy,
Chief Scientific Officer -
Jeffrey F. Biunno CPA, M.B.A., CPA, MBA,
CFO, Treasurer & Sec. -
Kenneth Cundy,
Chief Scientific Officer -
David Greenwood,
Independent Director -
Jeffrey Biunno,
Chief Financial Officer, Treasurer, Secretary -
Jon Stern,
Director -
Misha Petkevich,
Independent Director -
Albion Fitzgerald,
Independent Chairman of the Board -
Pinchas Cohen,
Independent Director -
Nir Barzilai,
Independent Director -
Jordyn Tarazi,
Director of Investor Relations -
Dr. Rohit Loomba,
Scientific Consultant -
Dr. Changhan David Lee Ph.D.,
Consultant of Mitochondrial Biology -
Dr. David Andrew Sinclair A.O., Ph.D.,
Co-Founder, Advisor & Consultant -
Dr. Joseph J. Sarret,
CEO & Director -
Simon Allen,
Chief Executive Officer -
Marc E. Goldberg,
-
Philippe Calais,
Director -
Joseph J. Sarret,
Chief Executive Officer -
John Amatruda,
Director -
Carol Nast,
Director -
Joanne Yun,
Director -
Stephanie Tozzo,
Director